• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

动力学效应模型及其应用。

Kinetic-effect models and their applications.

作者信息

Grevel J

机构信息

Department of Pharmacology, University of Texas Medical School, Houston 77030.

出版信息

Pharm Res. 1987 Apr;4(2):86-91. doi: 10.1023/a:1016402616081.

DOI:10.1023/a:1016402616081
PMID:3334411
Abstract

This article focuses on mathematical models that analyze the time course of drug effects in humans. Any such model, whether parametric or nonparametric, is termed a kinetic-effect model (KEM). These models serve to describe (interpolation) and to predict (extrapolation) the effect-time profile. KEMs are applicable to many problems in pharmaceutics, pharmacology, and clinical pharmacology.

摘要

本文聚焦于分析药物在人体中作用时间过程的数学模型。任何此类模型，无论是参数模型还是非参数模型，都被称为动力学效应模型（KEM）。这些模型用于描述（内插）和预测（外推）效应-时间曲线。KEMs适用于药剂学、药理学和临床药理学中的许多问题。

相似文献

1
Kinetic-effect models and their applications.动力学效应模型及其应用。
Pharm Res. 1987 Apr;4(2):86-91. doi: 10.1023/a:1016402616081.
2
Modelling during drug development.
Eur J Pharm Biopharm. 2000 Jul;50(1):13-26. doi: 10.1016/s0939-6411(00)00083-7.
3
Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.药理学与临床药理学中定量方法的引入：历史概述
Clin Pharmacol Ther. 2007 Jul;82(1):3-6. doi: 10.1038/sj.clpt.6100248.
4
Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.基于生理学的药代动力学与 ADME 的体外-体内外推相结合：系统药理学拱门下的联姻。
Clin Pharmacol Ther. 2012 Jul;92(1):50-61. doi: 10.1038/clpt.2012.65. Epub 2012 May 30.
5
Integrated pharmacokinetics and pharmacodynamics in drug development.药物研发中的整合药代动力学与药效学
Clin Pharmacokinet. 2007;46(9):713-37. doi: 10.2165/00003088-200746090-00001.
6
Clinical Studies for the Sake of Negative Data: The Proof Is in the Pudding.为获取阴性数据而开展的临床研究：实践出真知。
Clin Transl Sci. 2018 Nov;11(6):535-536. doi: 10.1111/cts.12568. Epub 2018 Jul 10.
7
Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development.药代动力学-药效学模型在早期临床药物开发中的影响。
Eur J Pharm Sci. 2017 Nov 15;109S:S53-S58. doi: 10.1016/j.ejps.2017.05.042. Epub 2017 May 20.
8
Models of physiology and physiologically based models in clinical pharmacology.生理学模型和临床药理学中的基于生理学的模型。
Clin Pharmacol Ther. 2012 Jul;92(1):3-6. doi: 10.1038/clpt.2012.67.
9
Qualitative pharmacokinetic modeling of drugs.药物的定性药代动力学建模
AMIA Annu Symp Proc. 2005;2005:71-5.
10
The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement.基于生理学的药代动力学建模的成功与失败：仍有改进空间。
Expert Opin Drug Metab Toxicol. 2014 May;10(5):631-5. doi: 10.1517/17425255.2014.888058. Epub 2014 Feb 11.

引用本文的文献

1
Methodological issues in pharmacokinetic-pharmacodynamic modelling.药代动力学-药效学建模中的方法学问题。
Clin Pharmacokinet. 1998 Aug;35(2):151-66. doi: 10.2165/00003088-199835020-00004.
2
Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.苯二氮䓬类药物的药代动力学-药效学关系
Clin Pharmacokinet. 1996 Jan;30(1):52-76. doi: 10.2165/00003088-199630010-00004.
3
Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.药物研发I期/II期的药代动力学-药效学关系。

本文引用的文献

1
Drug concentration, binding, and effect in vivo.体内的药物浓度、结合和效应。
Pharm Res. 1984 May;1(3):102-5. doi: 10.1023/A:1016367701698.
2
Some suggestions for measuring predictive performance.一些关于衡量预测性能的建议。
J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12. doi: 10.1007/BF01060893.
3
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.理解剂量-效应关系：药代动力学-药效学模型的临床应用
Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):49-59. doi: 10.1007/BF03220008.
Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53. doi: 10.2165/00003088-198106060-00002.
4
Pharmacokinetic and pharmacodynamic modeling in vivo.体内药代动力学和药效学建模
Crit Rev Bioeng. 1981;5(4):273-322.
5
Kinetics of interaction between drugs and biological systems.药物与生物系统之间的相互作用动力学。
Farmaco Sci. 1968 Oct;23(10):907-18.
6
Correlation of performance test scores with "tissue concentration" of lysergic acid diethylamide in human subjects.人体受试者中麦角酸二乙酰胺的性能测试分数与“组织浓度”的相关性。
Clin Pharmacol Ther. 1968 Sep-Oct;9(5):635-8. doi: 10.1002/cpt196895635.
7
Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man.人体β-肾上腺素能阻滞定量评估中的血浆普萘洛尔水平
Br Med J. 1970 Sep 26;3(5725):731-4. doi: 10.1136/bmj.3.5725.731.
8
Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application.药物剂量优化的反馈控制方法。概念、分类及临床应用。
Clin Pharmacokinet. 1985 Nov-Dec;10(6):457-76. doi: 10.2165/00003088-198510060-00001.
9
Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model.通过整合药代动力学-药效学模型描述多巴胺激动剂CQP201-403催乳素抑制作用的时间过程。
Br J Clin Pharmacol. 1986 Jul;22(1):1-13. doi: 10.1111/j.1365-2125.1986.tb02872.x.
10
Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.使用非参数动力学和动力学模型对药代动力学和药效学进行同时建模。
Clin Pharmacol Ther. 1986 Jul;40(1):86-93. doi: 10.1038/clpt.1986.143.